Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice

PHASE2RecruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

March 23, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

June 30, 2025

Conditions
Neonatal JaundiceMicrotiaPregnancy RelatedHyperbilirubinemia, Neonatal
Interventions
DIETARY_SUPPLEMENT

Vivomixx®

The probiotic group participants will receive 1 sachet of probiotic product daily from 36weeks of gestation up to 7th day of postpartum while placebo groups will 1 sachet placebo prepared with the same colour, taste, and packaging with Vivomixx® daily for the same duration of probiotic groups. Vivomixx® is a non-genetically modified (GMO), gluten-free, high potency microbiotic food supplement, containing eight strains (Streptococcus thermophilus DSM24731® / NCIMB 30438, Bifidobacterium breve DSM24732® / NCIMB 30441, Bifidobacterium longum DSM24736® / NCIMB 30435, Bifidobacterium infantis DSM24737® / NCIMB 30436\*, Lactobacillus acidophilus DSM24735® / NCIMB 30442, Lactobacillus plantarum DSM24730® / NCIMB 30437, Lactobacillus paracasei DSM24733® / NCIMB 30439, Lactobacillus delbrueckii subsp. bulgaricus DSM24734® / NCIMB 30440) of live bacteria (450 billion bacteria per sachet).

DIETARY_SUPPLEMENT

Placebo

A maltose- containing product with a similar phenotype with Vivomixx®.

Trial Locations (1)

0852

RECRUITING

Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER